Geneva, May 28 -- International Clinical Trials Registry received information related to the study (ACTRN12625000387426) titled 'CLL11 - A study to evaluate the efficacy of Epcoritamab consolidation in high genomic risk and Measurable Residual Disease (MRD)-positive Chronic Lymphocytic Leukaemia (CLL) patients after first-line venetoclax and obinutuzumab' on May 1.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Non-randomised trial
Primary Sponsor: Australasian Leukaemia and Lymphoma Group (ALLG)
Condition:
Chronic Lymphocytic Leukaemia
Chronic Lymphocytic Leukaemia
Cancer - Leukaemia - Chronic leukaemia
Intervention:
Epcoritamab is supplied as a concentrate for solution for intended subcutaneous injection...